# Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

> **NCT03856112** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- t(11;14) Negative

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib
- **DRUG:** Ixazomib Citrate
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03856112
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-21
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Per CTEP, Martha Khrum this study is withdrawn. Changing status to update CT.gov
- **Last updated:** 2019-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856112, "Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03856112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*